Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04058756 · ClinicalTrials.gov registry record · Phase 1

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

A Phase 1 study of Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
120
Enrollment target
20
Study locations

NCT04058756 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 120 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04058756, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG PDR001

Study Locations (20)

Other

  • Novartis Investigative Site - Leuven
  • Novartis Investigative Site - Liège
  • Novartis Investigative Site - Guangzhou
  • Novartis Investigative Site - Brno
  • Novartis Investigative Site - Lille
  • Novartis Investigative Site - Lyon
  • Novartis Investigative Site - Marseille
  • Novartis Investigative Site - Marseille
  • Novartis Investigative Site - Villejuif
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - Heidelberg
  • Novartis Investigative Site - Ulm
  • Novartis Investigative Site - High West

New York

  • Columbia University Medical Center - New York

Oregon

  • Providence Portland Medical Center - Portland

Texas

  • MD Anderson Cancer Center Uni of Te - Houston

Ontario

  • Novartis Investigative Site - Toronto

Quebec

  • Novartis Investigative Site - Montreal

Guangdong

  • Novartis Investigative Site - Guangzhou

Thuringia

  • Novartis Investigative Site - Jena

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2019-10-30
Est. Completion 2030-04-30
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04058756

The ClinicalTrials.gov registry entry for NCT04058756 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (39% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PDR001 is the first listed.

NCT04058756 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, Oregon.

Frequently Asked Questions

What is clinical trial NCT04058756 about?

NCT04058756 is a clinical study titled "Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments". The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.

What is the current status of trial NCT04058756?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2019-10-30. Estimated completion is 2030-04-30.

What conditions does trial NCT04058756 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT04058756?

The interventions under investigation include: PDR001 (DRUG).

Who is sponsoring clinical trial NCT04058756?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04058756 being conducted?

This trial has 20 study locations across New York, Oregon, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.